Stockscreener 앱 받기
44.01
17.71%
6.62
시간 외 거래:
44.05
0.04
+0.09%
Agios Pharmaceuticals Inc 주식(AGIO)의 최신 뉴스
Why Is Agios Pharma Stock Soaring Tuesday? - Benzinga
Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related) - AOL.com
AGIO Maintained by RBC Capital -- Price Target Raised to $32 - GuruFocus
Agios Pharmaceuticals (AGIO) Receives Priority Review from FDA f - GuruFocus
Agios Pharmaceuticals (AGIO) Sees 13.5% Surge - GuruFocus
AGIO Stock Jumps As Mitapivat Sickle Cell Data Fuels Hype - StocksToTrade
Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related) - The Motley Fool
AGIO Stock Hits Over 7-Month Highs – FDA Catalyst, ‘Seasonally Strong’ Q2 Earnings Estimate Drive Optimism - Yahoo Finance
Agios Pharmaceuticals (AGIO) Secures FDA Priority Review for Mit - GuruFocus
Agios Pharmaceuticals Shares Rise After FDA Grants Priority Review for Sickle Cell Treatment - marketscreener.com
DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday - Benzinga
Agios Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $42.62, Implies 14% Upside - TradingView
AGIO Maintained by B of A Securities -- Price Target Raised to $46 - GuruFocus
Agios Pharmaceuticals (AGIO) Gains FDA Priority Review for Pyruk - GuruFocus
Agios Pharmaceuticals (AGIO) Receives FDA Priority Review for Mi - GuruFocus
RBC Capital Adjusts Agios Pharmaceuticals PT to $32 From $28, Maintains Sector Perform Rating - marketscreener.com
Agios gains FDA priority review for Pyrukynd label expansion - Seeking Alpha
Agios Says US FDA Grants Priority Review for Mitapivat to Treat Sickle Cell Disease - marketscreener.com
FDA accepts Agios sNDA for mitapivat in sickle cell disease By Investing.com - Investing.com Canada
FDA puts Agios' sickle cell drug on fast track to Nov. 1 review date - Stock Titan
Price to sales forward of Agios Pharmaceuticals, Inc. – MUN:8AP - TradingView
The Technical Signals Behind (AGIO) That Institutions Follow - Stock Traders Daily
Price to book forward of Agios Pharmaceuticals, Inc. – NASDAQ:AGIO - TradingView
AGIOAgios Pharmaceuticals Inc Latest SEC Filings - Finviz
Agios Pharmaceuticals: CMO Sarah Gheuens sells $150,502 in stock - Investing.com
Agios Pharmaceuticals: CMO Sarah Gheuens sells $150,502 in stock By Investing.com - Investing.com India
D. E. Shaw reports 3.03M-share stake in Agios (AGIO) - Stock Titan
Agios (NASDAQ: AGIO) CMO nets shares after RSU vesting and tax sale - Stock Titan
AGIO (NASDAQ: AGIO) affiliate notifies plan to offer 4,007 shares via broker - Stock Titan
Agios Pharmaceuticals, Inc.(NasdaqGS: AGIO) dropped from Russell 2000 Defensive Index - marketscreener.com
Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Agios Pharmaceuticals, Inc.(NasdaqGS: AGIO) added to Russell 2500 Growth Benchmark - marketscreener.com
Agios Pharmaceuticals to announce Q2 2026 results on July 30 - scanx.trade
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET - The Manila Times
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at ... - Caledonian Record
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 A.m. ET - Moomoo
Agios Pharmaceuticals, Inc.(NasdaqGS: AGIO) added to Russell 2000 Growth Benchmark - marketscreener.com
Agios Pharmaceuticals, Inc.(NasdaqGS: AGIO) added to Russell 3000E Growth Benchmark - marketscreener.com
Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) dropped from Russell 2000 Value-Defensive Index - marketscreener.com
Agios Pharmaceuticals, Inc.(NasdaqGS: AGIO) added to Russell 3000 Growth Benchmark - marketscreener.com
Agios Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AGIO) - TradingView
Agios Pharmaceuticals Insider Lowered Holding By 91% During Last Year - Moomoo
Agios Pharmaceuticals, Inc. Actuals & Estimates (DUS:8AP) - TradingView
Agios Pharmaceuticals, Inc. Actuals & Estimates (MUN:8AP) - TradingView
AGIO stock surges 35% in six months: What's driving it? - MSN
AGIO Forecast — Price Target — Prediction for 2027 - TradingView
0HB0 Forecast — Price Target — Prediction for 2027 - TradingView
Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026) - AOL.com
Precision Trading with Agios Pharmaceuticals Inc. (AGIO) Risk Zones - Stock Traders Daily
Agios to discontinue candidate for myelodysplastic syndromes - MSN
A Quick Look at Today's Ratings for Agios Pharmaceuticals(AGIO.US), With a Forecast Between $36 to $54 - Moomoo
Agios Pharmaceuticals (AGIO) Is Up 10.3% After New Mitapivat Phase 3 Data and Share Filing – Has The Bull Case Changed? - Sahm
Truist Financial Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Announces Target Price $36 - Moomoo
Agios (NASDAQ: AGIO) director exercises RSUs and gains new equity awards - Stock Titan
Agios (NASDAQ: AGIO) director receives new stock options and RSU awards - Stock Titan
Agios Pharmaceuticals (AGIO) director reports new equity awards and RSU vesting - Stock Titan
Agios (NASDAQ: AGIO) director receives new options and RSU awards - Stock Titan
AGIOS (AGIO) director Maykin Ho exercises RSUs and receives new equity awards - Stock Titan
Agios (NASDAQ: AGIO) director receives stock options, RSUs and exercises units - Stock Titan
Agios Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Owen Adams Catherine - Moomoo
Agios Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Scadden David - Moomoo
AGIOS (AGIO) director Scadden exercises RSUs and receives new stock option and RSU awards - Stock Titan
Agios Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Smith Cynthia - Moomoo
Agios (NASDAQ: AGIO) director reports RSU exercise and new equity grants - Stock Titan
Agios Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Viswanadhan Krishnan - Moomoo
Agios (NASDAQ: AGIO) grants Viswanadhan 6,000 RSU and performance share units - Stock Titan
Agios (NASDAQ: AGIO) CEO Brian Goff receives 39,000 stock-based awards - Stock Titan
Agios Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Goff Brian - Moomoo
[Form 4] AGIOS PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
1.17%
2.48%
자본화:
|
볼륨(24시간):